SEARCH

SEARCH BY CITATION

References

  • 1
    Omland LH, Jepsen P, Krarup H, et al. Increased mortality among persons infected with hepatitis C virus. Clin Gastroenterol Hepatol 2011; 9: 718.
  • 2
    Omland LH, Krarup H, Jepsen P, et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010; 53: 3642.
  • 3
    Muhlberger N, Schwarzer R, Lettmeier B, et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009; 9: 34.
  • 4
    Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 51321.
  • 5
    Sroczynski G, Esteban E, Conrads-Frank A, et al. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Public Health 2009; 19: 24553.
  • 6
    Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 14862.
  • 7
    Chiquete E, Panduro A. Low prevalence of anti-hepatitis C virus antibodies in Mexico: a systematic review. Intervirology 2007; 50: 18.
  • 8
    Abdel-Hamid M, El-Daly M, El-Kafrawy S, et al. Comparison of second- and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus. J Clin Microbiol 2002; 40: 16569.
  • 9
    Kershenobich D, Razavi HA, Cooper CL, et al. Applying a system approach to forecast the total HCV-infected population size – model validation using US data. Liver Int 2011; 31(Suppl. 2): 419.
  • 10
    Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe – a review. Euro Surveill 2008; 13: 18.
  • 11
    European Centre for Disease Prevention and Control. Annual Epidemiological Report on Communicable Diseases in Europe 2009. Report on the State of Communicable Diseases in Europe 2009, Revised Edition. European Centre for Disease Prevention and Control, Stockholm, 2010.
  • 12
    Remis RS. Modelling the Incidence and Prevalence of Hepatitis C Infection and Its Sequelae in Canada, 2007: Final Report. Community Acquired Infections Division, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, 2009. Available at http://epe.lac-bac.gc.ca/100/200/301/phac-aspc/modeling_hepatis_c_infection-e/HP40-39-2009E.pdf (accessed 26 March 2011).
  • 13
    Enhanced Hepatitis Strain Surveillance System. Health Canada. Epidemiology of Acute Hepatitis C Infection in Canada. Results from the Enhanced Hepatitis Strain Surveillance System (EHSSS). Ottawa: Centre for Communicable Diseases and Infection Control, 2009.
  • 14
    Public Health Agency of Canada. Evaluation of the Hepatitis C Prevention, Support and Research Program 1999/2000–2005/2006. Ottowa: Public Health Agency of Canada, 2008.
  • 15
    Remis Robert S. A Study to Characterize the Epidemiology of Hepatitis C Infection in Canada, 2002: Final Report/Prepared by Robert S. Remis Computer File. Hepatitis C Prevention, Support and Research Program, Public Health Agency of Canada, 2008.
  • 16
    Zahariadis G, Plitt SS, O'Brien S, et al. Prevalence and estimated incidence of blood-borne viral pathogen infection in organ and tissue donors from northern Alberta. Am J Transplant 2007; 7: 22634.
  • 17
    Manuel DG, Johnson I, Fearon M, Hockin J. The prevalence of hepatitis C in a community-based population, Ontario, 1996. Can Commun Dis Rep 1999; 25: 1939.
  • 18
    Public Health Agency of Canada. Notifiable Diseases Online 2005, 1991–2004. Available at http://dsol-smed.hc-sc.gc.ca/dsol-smed/ndis/c_inda-eng.php
  • 19
    Marotta P, Cooper CL, Wong DK, et al. Impact of advanced fibrosis and cirrhosis on sustained virologic response of HCV G1-infected patients: results of the Canadian power program (Abstract #1216). 58th annual meeting of the American Association for the Study of Liver Diseases, 31 October–4 November 2008. San Francisco, California, USA. Hepatology 2008; 48 (Suppl. 1): 849A.
  • 20
    Antonishyn NA, Ast VM, McDonald RR, et al. Rapid genotyping of hepatitis C virus by primer-specific extension analysis. J Clin Microbiol 2005; 43: 515863.
  • 21
    Chaudhary RK, Tepper M, Eisaadany S, Gully PR. Distribution of hepatitis C virus genotypes in Canada: results from the LCDC Sentinel Health Unit Surveillance System. J Can Infect Dis 1999; 10: 536.
  • 22
    Bernier L, Willems B, Delage G, Murphy DG. Identification of numerous hepatitis C virus genotypes in Montreal, Canada. J Clin Microbiol 1996; 34: 28158.
  • 23
    Murphy DG, Willems B, Delage G, et al. Hepatitis C virus genotypes in patients and blood donors – Quebec. Can Commun Dis Rep 1995; 21: 12932.
  • 24
    Andonov A, Chaudhary RK. Genotyping of Canadian hepatitis C virus isolates by PCR. J Clin Microbiol 1994; 32: 20314.
  • 25
    Frankova S. Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Screening for hepatitis C in the Czech Republic. Conversation with Largen A, Center for Disease Analysis, Kromite, Louisville, CO, USA, 14 November 2010.
  • 26
    Krekulova L, Rehak V, Strunecky O, Nemecek V. Current situation and trends in the hepatitis C virus genotype distribution among injecting drug users in the Czech Republic. Epidemiol Mikrobiol Imunol 2009; 58: 849.
  • 27
    Urbanek P, Marecek Z, Brodanova M, et al. Risk factors for transmission of hepatitis C in the the Czech population. Cas Lek Cesk 2002; 141: 1858.
  • 28
    Krekulova L, Rehak V, Madrigal N, et al. Genotypic and epidemiologic characteristics of hepatitis C virus infections among recent injection drug user and nonuser populations. Clin Infect Dis 2001; 33: 14358.
  • 29
    Hobstova J, Vitous A. Infectious diseases of drug users in the Czech Republic. Cas Lek Cesk 2007; 146: 13741.
  • 30
    Zabransky T, Mravcik V, Korcisova B, Rehak V. Hepatitis C virus infection among injecting drug users in the Czech Republic – prevalence and associated factors. Eur Addict Res 2006; 12: 15160.
  • 31
    Nemecek V, Castkova J, Fritz P, et al. The 2001 serological survey in the Czech Republic – viral hepatitis. Cent Eur J Public Health 2003; 11 (Suppl.): S5461.
  • 32
    Klofera M, Chalupa P, Jezek P. Hepatitis C antibodies (anti-HCV) in blood donors at the transfusion department in Brno. Cas Lek Cesk 1994; 133: 45962.
  • 33
    Nemecek V, Strunecky O. Genotypic heterogeneity of hepatitis C virus (HCV) from blood donors in the Czech Republic. Epidemiol Mikrobiol Imunol 2009; 58: 6372.
  • 34
    Delarocque-Astagneau E, Meffre C, Dubois F, et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat 2010; 17: 43543.
  • 35
    Jullien-Depradeux AM, Bloch J, Le Quellec-Nathan M, Abenhaim A. National campaign against hepatitis C in France (1999–2002). Acta Gastroenterol Belg 2002; 65: 1124.
  • 36
    Dubois F, Desenclos JC, Mariotte N, Goudeau A. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group. Hepatology 1997; 25: 14906.
  • 37
    Meffre C, Le Strat Y, Delarocque-Astagneau E, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol 2010; 82: 54655.
  • 38
    King LA, Le Strat Y, Meffre C, Delarocque-Astagneau E, Desenclos JC. Assessment and proposal of a new combination of screening criteria for hepatitis C in France. Eur J Public Health 2009; 19: 52733.
  • 39
    Foucher J, Reiller B, Jullien V, et al. FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study. J Viral Hepat 2009; 16: 12131.
  • 40
    Delarocque-Astagneau E, Pillonel J, De Valk H, et al. An incident case–control study of modes of hepatitis C virus transmission in France. Ann Epidemiol 2007; 17: 75562.
  • 41
    Karmochkine M, Carrat F, Dos Santos O, Cacoub P, Raguin G. A case–control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. J Viral Hepat 2006; 13: 77582.
  • 42
    Courouce AM, Pillonel J, Saura C. Screening for markers of infections transmitted by transfusions in the blood collected in France from 1996 to 1998. Transfus Clin Biol 2000; 7: 15370.
  • 43
    Michault A, Faulques B, Sevadjan B, et al. Prevalence of hepatitis A, B, C virus markers in Reunion (south hospital and Saint Pierre prison). Bull Soc Pathol Exot 2000; 93: 3440.
  • 44
    Nalpas B, Zylberberg H, Dubois F, et al. Prevalence of infection by hepatitis viruses in a rural area. Analysis according to risk factors and alcohol consumption. Gastroenterol Clin Biol 2000; 24: 53640.
  • 45
    Ouzan D, Pesle B, Baldini E, et al. Epidemiological information obtained from anti-hepatitis C virus screening in blood donors and candidates for autologous transfusion from 1992 to 1996 in the Alpes-Maritimes region. Gastroenterol Clin Biol 2000; 24: 33741.
  • 46
    Pradat P, Trepo C. HCV: epidemiology, modes of transmission and prevention of spread. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 20110.
  • 47
    Frere T, Verneau A, Besson I, et al. Treatment of hepatitis C virus infection in the Poitou-Charentes region. Gastroenterol Clin Biol 1999; 23: 88791.
  • 48
    Merle V, Goria O, Gourier-Frery C, et al. Risk factors of contamination by hepatitis C virus. Case–control study in the general population. Gastroenterol Clin Biol 1999; 23: 43946.
  • 49
    Raguin G, Rosenthal E, Cacoub P, et al. Hepatitis C in France: a national survey in the Departments of Internal Medicine and Infectious Diseases. The GERMIVIC (Joint Study Group on Hepatitis C virus of the French National Society of Internal Medicine and the French Society of Infectious Diseases). Eur J Epidemiol 1998; 14: 5458.
  • 50
    Bastie A, Pawlotsky JM, Roudot-Thoraval F, Dhumeaux D. Hepatitis C virus infection. Epidemiology. Pathol Biol 1995; 43: 67480.
  • 51
    Maisonneuve P, Aymard JP, Lemaire JM, Baillet A, Janot C. Serum antibodies to hepatitis C virus: analysis of risk factors of seropositivity in a population of blood donors in metropolitan France. Rev Med Interne 1991; 12: 4168.
  • 52
    Roudot-Thoraval F. Epidemiology of infections linked to hepatitis C virus in France. Bull Acad Natl Med 1996; 180: 125362.
  • 53
    Saura C, Pillonel J, Courouce AM. Screening for markers of blood-borne diseases in donated units collected in France from 1993 to 1995. Transfus Clin Biol 1997; 4: 40315.
  • 54
    French Institute for Public Health Surveillance (InVS). Institut de veille sanitaire. Hepatite C. Surveillance nationale de l'hepatite C a partir des poles de reference volontaires. Donnees 2001–2007.2010 Available at http://www.invs.sante.fr/surveillance/hepatite_c/poleref_volontaire/2001_2007/web-2007v2.pdf (accessed 28 September 2010).
  • 55
    Defossez G, Verneau A, Ingrand I, et al. Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: a comparative cross-sectional study in Poitou-Charentes region. Eur J Gastroenterol Hepatol 2008; 20: 36772.
  • 56
    Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat 1999; 6: 43543.
  • 57
    Payan C, Roudot-Thoraval F, Marcellin P, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat 2005; 12: 40513.
  • 58
    Pradat P, Caillat-Vallet E, Sahajian F, et al. Prevalence of hepatitis C infection among general practice patients in the Lyon area, France. Eur J Epidemiol 2001; 17: 4751.
  • 59
    Desenclos JC. Epidemiology of hepatitis C. Rev Prat 2000; 50: 106670.
  • 60
    Lefrere JJ. Descriptive epidemiology of hepatitis C virus infection in France in 1996. Transfus Clin Biol 1997; 4: 299319.
  • 61
    Jauffret-Roustide M, Le Strat Y, Couturier E, et al. A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infect Dis 2009; 9: 113.
  • 62
    Jauffret-Roustide M, Emmanuelli J, Desenclos JC. Limited impact of the harm-reduction policy on HCV among drug-users. The ANRS-Coquelicot survey example. Rev Epidemiol Sante Publique 2006; 54 (Spec No 1): 1S539.
  • 63
    Pillonel J, David D, Pinget R, Laperche S. Prevalence of HBV, HCV, HIV and HTLV in autologous blood donors in France between 1993 and 2000. Transfus Clin Biol 2002; 9: 28996.
  • 64
    Botte C, Janot C. Epidemiology of HCV infection in the general population and in blood transfusion. Nephrol Dial Transplant 1996; 11: 1921.
  • 65
    Aymard JP, Botte C, Contal P, Janot C, Streiff F. Seroprevalence of hepatitis C antibodies among blood donors. Study of second generation ELISA and RIBA tests and surrogate markers. Pathol Biol 1993; 41: 14953.
  • 66
    Aguelles O, Janot C. Epidemiology of anti-HCV antibodies in France. Viral Hepatitis Study Group of the French Blood Transfusion Society. Arch Virol Suppl 1992; 4: 24952.
  • 67
    Aymard JP, Janot C, Adjizian JC, et al. Serum antibodies against hepatitis C: study of 4,100 blood donors from the northeast of France. Rev Fr Transfus Hemobiol 1990; 33: 295302.
  • 68
    Ranger S, Martin P, Roussanne MC, Denis F. Prevalence of hepatitis C virus antibodies in the general population and in selected groups of patients in Limoges, France. Gut 1993; 34: S501.
  • 69
    Larsen C, Pialoux G, Salmon D, et al. Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. Euro Surveill 2008; 13: 14.
  • 70
    Sahajian F, Vanhems P, Bailly F, et al. Screening campaign of hepatitis C among underprivileged people consulting in health centres of Lyon area, France. Eur J Public Health 2007; 17: 26371.
  • 71
    Ouzan D, Cavailler P, Hofliger P, et al. Modalities of care in anti HCV positive patients identified in General Medicine in the Alpes-Maritimes district. Gastroenterol Clin Biol 2003; 27: 37680.
  • 72
    Roudot-Thoraval F, Monnet E, Mercet P, et al. Strategies of hepatitis C screening in general practice. Results of a two-center randomized trial. Gastroenterol Clin Biol 2000; 24: 103741.
  • 73
    Djeriri K, Fontana L, Laurichesse H, et al. Seroprevalence of markers of viral hepatitis A, B and C in hospital personnel at the Clermont-Ferrand University Hospital Center. Presse Med 1996; 25: 14550.
  • 74
    Roudot-Thoraval F, Deforges L, Girollet PP, et al. Prevalence of hepatitis C virus antibodies (tests ELISA 2 and RIBA 2) in a population of pregnant women in France. Gastroenterol Clin Biol 1992; 16: 2559.
  • 75
    Bruandet A, Lucidarme D, Decoster A, et al. Incidence and risk factors of HCV infection in a cohort of intravenous drug users in the North and East of France. Rev Epidemiol Sante Publique 2006; 54 (Spec No 1): 1S1522.
  • 76
    Lucidarme D, Bruandet A, Ilef D, et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol Infect 2004; 132: 699708.
  • 77
    Simon N, Courouce AM, Lemarrec N, Trepo C, Ducamp S. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int 1994; 46: 50411.
  • 78
    Cantaloube JF, Gallian P, Attoui H, et al. Genotype distribution and molecular epidemiology of hepatitis C virus in blood donors from southeast France. J Clin Microbiol 2005; 43: 36249.
  • 79
    Henquell C, Cartau C, Abergel A, et al. High prevalence of hepatitis C virus type 5 in central France evidenced by a prospective study from 1996 to 2002. J Clin Microbiol 2004; 42: 30305.
  • 80
    Tamalet C, Colson P, Tissot-Dupont H, et al. Genomic and phylogenetic analysis of hepatitis C virus isolates: a survey of 535 strains circulating in southern France. J Med Virol 2003; 71: 3918.
  • 81
    Bourliere M, Barberin JM, Rotily M, et al. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat 2002; 9: 6270.
  • 82
    Elghouzzi MH, Bouchardeau F, Pillonel J, et al. Hepatitis C virus: routes of infection and genotypes in a cohort of anti-HCV-positive French blood donors. Vox Sang 2000; 79: 13844.
  • 83
    Stuyver L, Fretz C, Esquivel C, et al. Hepatitis C virus (HCV) genotype analysis in apparently healthy anti-HCV-positive Parisian blood donors. Transfusion 1996; 36: 5528.
  • 84
    Gournay J, Marcellin P, Martinot-Peignoux M, et al. Hepatitis C virus genotypes in French blood donors. J Med Virol 1995; 45: 399404.
  • 85
    Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 1995; 171: 160710.
  • 86
    Sarrazin C, Berg T, Ross RS, et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 2010; 48: 289351.
  • 87
    Robert Koch Institute. Zur Situation wichtiger Infektionskrankheiten in Deutschland: virus hepatitis B, C und D im Jahr 2009. Epi Bull 2010; 20: 17790.
  • 88
    Huppe D, Zehnter E, Mauss S, et al. Epidemiology of chronic hepatitis C in Germany-an analysis of 10,326 patients in hepatitis centres and outpatient units. Z Gastroenterol 2008; 46: 3444.
  • 89
    Offergeld R, Faensen D, Ritter S, Hamouda O. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000–2002: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill 2005; 10: 811.
  • 90
    Deterding K, Wiegand J, Gruner N, et al. The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol 2009; 47: 53140.
  • 91
    Gerner P, Wirth S, Wintermeyer P, Walz A, Jenke A. Prevalence of hepatitis C virus infection in children admitted to an urban hospital. J Infect 2006; 52: 3058.
  • 92
    Wiegand J, Kaiser T, Lobstein S, et al. Low prevalence of chronic hepatitis C, but high prevalence of elevated aminotransferases in a cohort of 2026 patients referred for orthopaedic surgery in the eastern part of Germany. Z Gastroenterol 2006; 44: 114.
  • 93
    Ammon A, Reichart PA, Pauli G, Petersen LR. Hepatitis B and C among Berlin dental personnel: incidence, risk factors, and effectiveness of barrier prevention measures. Epidemiol Infect 2000; 125: 40713.
  • 94
    Weber B, Rabenau H, Berger A, et al. Seroprevalence of HCV, HAV, HBV, HDV, HCMV and HIV in high risk groups/Frankfurt a.M., Germany. Zentralbl Bakteriol 1995; 282: 10212.
  • 95
    Schlosser B, Domke D, Mockel M. High prevalence of chronic hepatitis C virus (HCV) infection in a German metropolitan area: a prospective screening analysis of 13,823 patients. The International Liver Congress 2009, 44th Annual Meeting of the European Association for the Study of the Liver, 22–26 April 2009, Copenhagen, Denmark, Poster (PDF), 2009.
  • 96
    Reimer J, Lorenzen J, Baetz B, et al. Multiple viral hepatitis in injection drug users and associated risk factors. J Gastroenterol Hepatol 2007; 22: 805.
  • 97
    Harder J, Walter E, Riecken B, et al. Hepatitis C virus infection in intravenous drug users Long-term follow-up after successful interferon therapy of acute hepatitis C. Clin Microbiol Infect 2004; 10: 76870.
  • 98
    Backmund M, Meyer K, Wachtler M, Eichenlaub D. Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur J Epidemiol 2003; 18: 5638.
  • 99
    Stark K, Schreier E, Muller R, et al. Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin. Scand J Infect Dis 1995; 27: 3317.
  • 100
    Wiegand J, Luz B, Mengelkamp AK, et al. Autologous blood donor screening indicated a lower prevalence of viral hepatitis in East vs West Germany: epidemiological benefit from established health resources. J Viral Hepat 2009; 16: 7438.
  • 101
    Koerner K, Cardoso M, Dengler T, Kerowgan M, Kubanek B. Estimated risk of transmission of hepatitis C virus by blood transfusion. Vox Sang 1998; 74: 2136.
  • 102
    Seidl S, Kuhnl P, Beyer J, et al. Hepatitis C virus (HCV) antibodies in German blood donors – a pilot study. Beitr Infusionsther 1990; 26: 1821.
  • 103
    Zimmermann R, Konig V, Bauditz J, et al. Examination of a Berlin blood donation branch for antibodies to hepatitis C virus with the anti-HCV test and for circulating HCV-RNA using polymerase chain reaction. Beitr Infusionsther 1992; 30: 3841.
  • 104
    Palitzsch KD, Hottentrager B, Schlottmann K, et al. Prevalence of antibodies against hepatitis C virus in the adult German population. Eur J Gastroenterol Hepatol 1999; 11: 121520.
  • 105
    Thierfelder W, Hellenbrand W, Meisel H, Schreier E, Dortschy R. Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol 2001; 17: 42935.
  • 106
    Lobstein S, Kaiser T, Liebert U, et al. Prevalence, aetiology and associated co-morbidities of elevated aminotransferases in a german cohort of orthopaedic surgery patients. Z Gastroenterol 2008; 46: 41520.
  • 107
    The Hepatitis C Trust. University of Southampton. The UK vs. Europe: Losing the fight against hepatitis C. London: The Hepatitis C Trust, 2006.
  • 108
    Schroter M, Zollner B, Schafer P, et al. Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance. J Clin Microbiol 2002; 40: 18668.
  • 109
    Ross RS, Viazov SO, Holtzer CD, et al. Genotyping of hepatitis C virus isolates using CLIP sequencing. J Clin Microbiol 2000; 38: 35814.
  • 110
    Berg T, Hopf U, Stark K, et al. Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters. J Hepatol 1997; 26: 48491.
  • 111
    Feucht HH, Schroter M, Zollner B, et al. The influence of age on the prevalence of hepatitis C virus subtypes 1a and 1b. J Infect Dis 1997; 175: 6858.
  • 112
    Feucht HH, Zollner B, Schroter M, et al. Distribution of genotypes and response to alpha-interferon in patients with hepatitis C virus infection in Germany. Eur J Clin Microbiol Infect Dis 1996; 15: 12832.
  • 113
    Savvas SP, Koskinas J, Sinani C, et al. Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. J Viral Hepat 2005; 12: 5517.
  • 114
    Katsoulidou A, Sypsa V, Tassopoulos NC, et al. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 2006; 13: 1927.
  • 115
    Gatselis NK, Rigopoulou E, Stefos A, Kardasi M, Dalekos GN. Risk factors associated with HCV infection in semi-rural areas of central Greece. Eur J Intern Med 2007; 18: 4855.
  • 116
    Gogos CA, Fouka KP, Nikiforidis G, et al. Prevalence of hepatitis B and C virus infection in the general population and selected groups in South-Western Greece. Eur J Epidemiol 2003; 18: 5517.
  • 117
    Raptopoulou M, Touloumi G, Tzourmakliotis D, et al. Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study. Hippokratia 2011; 15: 2631.
  • 118
    Goritsas C, Plerou I, Agaliotis S, et al. HCV infection in the general population of a Greek island: prevalence and risk factors. Hepatogastroenterology 2000; 47: 7825.
  • 119
    Panagopoulos P, Economou A, Kasimi A, et al. Prevalence of hepatitis B and C in the maternity department of a Greek district hospital. J Matern Fetal Neonatal Med 2004; 16: 10610.
  • 120
    Zervou EK, Boumba DS, Liaskos C, et al. Low prevalence of HCV, HIV, and HTLV-I/II infection markers in northwestern Greece: results of a 3-year prospective donor study (1995–1997). Eur J Intern Med 2003; 14: 3944.
  • 121
    Sypsa V, Hadjipaschali E, Hatzakis A. Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees. Eur J Epidemiol 2001; 17: 7218.
  • 122
    Koulentaki M, Spanoudakis S, Kantidaki E, et al. Prevalence of hepatitis B and C markers in volunteer blood donors in Crete. A 5-year study. J Viral Hepat 1999; 6: 2438.
  • 123
    Mazokopakis E, Vlachonikolis J, Philalithis A, Lionis C. Seroprevalence of hepatitis A, B and C markers in Greek warship personnel. Eur J Epidemiol 2000; 16: 106972.
  • 124
    Hadziyannis SJ, Giannoulis G, Hadziyannis E, et al. Hepatitis C virus infection in Greece and its role in chronic liver disease and hepatocellular carcinoma. J Hepatol 1993; 17 (Suppl. 3): S727.
  • 125
    Lionis C, Koulentaki M, Biziagos E, Kouroumalis E. Current prevalence of hepatitis A, B and C in a well-defined area in rural Crete, Greece. J Viral Hepat 1997; 4: 5561.
  • 126
    Koulentaki M, Ergazaki M, Moschandrea J, et al. Prevalence of hepatitis B and C markers in high-risk hospitalised patients in Crete: a five-year observational study. BMC Public Health 2001; 1: 17.
  • 127
    Raptopoulou-Gigi M, Orphanou E, Lalla TH, Lita A, Garifallos A. Prevalence of hepatitis C virus infection in a cohort of pregnant women in northern Greece and transmission of HCV from mother to child. Eur J Epidemiol 2001; 17: 2636.
  • 128
    Lionis C, Vlachonikolis IG, Skliros S, et al. Do undefined sources of hepatitis C transmission exist? The Greek study in General Practice. J Viral Hepat 2000; 7: 21824.
  • 129
    Michos A, Terzidis A, Kalampoki V, et al. Seroprevalence and risk factors for hepatitis A, B, and C among Roma and non-Roma children in a deprived area of Athens, Greece. J Med Virol 2008; 80: 7917.
  • 130
    Lionis C, Frangoulis E, Koulentakis M, Biziagos E, Kouroumalis E. Prevalence of hepatitis A, B, and C markers in school children of a rural area of Crete, Greece. Eur J Epidemiol 1997; 13: 41720.
  • 131
    Sypsa V, Touloumi G, Tassopoulos NC, et al. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepat 2004; 11: 36674.
  • 132
    Sypsa V, Touloumi G, Papatheodoridis GV, et al. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. J Viral Hepat 2005; 12: 54350.
  • 133
    Muller Z, Deak J, Horanyi M, et al. The detection of hepatitis C virus in South Hungary. J Clin Virol 2001; 20: 813.
  • 134
    Barna TK, Ozsvar Z, Szendrenyi V, Gal G. Hepatitis C virus antibody in the serum of blood donors. Orv Hetil 1996; 137: 50711.
  • 135
    Merkinaite S. HCV infection in Europe. Siauliu St. 5/1-21, Vilnius 01133, Lithuania: Eurasian Harm Reduction Network (EHRN), formerly Central and Eastern European Harm Reduction Network (CEEHRN), 1 October 2007.
  • 136
    European Monitoring Centre for Drugs and Drug Addiction. EMCDDA 2010 Selected Issue-Trends in Injecting Drug use in Europe European Union. Annual Report. Selected Issues/European Monitoring Centre for Drugs and Drug Addicton. European Monitoring Centre for Drugs and Drug Addiction, 2010, 22pp.
  • 137
    Mihaly I, Telegdy L, Ibranyi E, et al. Prevalence, genotype distribution and outcome of hepatitis C infections among the employees of the Hungarian Central Hospital for infectious diseases. J Hosp Infect 2001; 49: 23944.
  • 138
    McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32: 88492.
  • 139
    Gervain J, Simon G Jr, Papp I, Szabone BK. Determination of the type and subtype of the hepatitis C virus in chronic viral hepatitis patients in Hungary. Orv Hetil 2001; 142: 13159.
  • 140
    Sarvari C, Ujhelyi E, Szlávik J, et al Determination of hepatitis C virus genotypes in Hungary using the Trugene HCV 5'NC genotyping test. ISMD2010 Eighth International Symposium on Molecular Diagnostics 2010 Graz, Austria De Gruyter 2010, A21.
  • 141
    Muller Z, Deak J, Ross RS, et al. Hepatitis C virus genotypes in Hungarian and Austrian patients with chronic hepatitis C. J Clin Virol 2003; 26: 295300.
  • 142
    Zuckerman E. Liver Unit, Carmel Medical Center, Haifa, Israel. Hepatitis C in Israel. Conversation with Razavi HA. Center for Disease Analysis, Kromite, Louisville, CO, USA, 2 October 2010.
  • 143
    Kerzman H, Green MS, Shinar E. Risk factors for hepatitis C virus infection among blood donors in Israel: a case–control study between native Israelis and immigrants from the former Soviet Union. Transfusion 2007; 47: 118996.
  • 144
    Glikberg F, Brawer-Ostrovsky J, Ackerman Z. Very high prevalence of hepatitis B and C in Bukharian Jewish immigrants to Israel. J Clin Gastroenterol 1997; 24: 303.
  • 145
    Lurie Y, Landau DA, Blendis L, et al. Acute hepatitis C in Israel: a predominantly iatrogenic disease? J Gastroenterol Hepatol 2007; 22: 15864.
  • 146
    Almog R, Low M, Cohen D, et al. Prevalence of anti-hepatitis A antibodies, hepatitis B viral markers, and anti-hepatitis C antibodies among immigrants from the former USSR who arrived in Israel during 1990–1991. Infection 1999; 27: 2127.
  • 147
    Flatau E, Segol O, Shneour A, Tabenkin H, Raz R. Prevalence of markers of infection with hepatitis B and C viruses in immigrants of operation Solomon, 1991. Isr J Med Sci 1993; 29: 3879.
  • 148
    Stern M, Manny N, Klein A, et al. A study of Israeli blood donors, asymptomatic carriers of hepatitis C virus, in relation to liver disease, cryoglobulinemia and transmission. Isr J Med Sci 1995; 31: 2779.
  • 149
    Bar-Shany S, Green MS, Slepon R, Shinar E. Ethnic differences in the prevalence of anti-hepatitis C antibodies and hepatitis B surface antigen in Israeli blood donors by age, sex, country of birth and origin. J Viral Hepat 1995; 2: 13944.
  • 150
    Shemer-Avni Y, el Astral Z, Kemper O, et al. Hepatitis C virus infection and genotypes in Southern Israel and the Gaza Strip. J Med Virol 1998; 56: 2303.
  • 151
    Zuckerman E. Liver Unit, Carmel Medical Center, Haifa, Israel. Sources for the epidemiology of hepatitis C in Israel. Conversation with Razavi HA. Center for Disease Analysis, Kromite, Louisville, CO, USA, 2 August 2010.
  • 152
    Loebstein R, Mahagna R, Maor Y, et al. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors. Isr Med Assoc J 2008; 10: 7758.
  • 153
    Maor Y, Bashari D, Kenet G, et al. Hepatitis C at the Israeli National Hemophilia Center. Haemophilia 2006; 12: 6874.
  • 154
    Sermoneta-Gertel S, Donchin M, Adler R, et al. Hepatitis c virus infection in employees of a large university hospital in Israel. Infect Control Hosp Epidemiol 2001; 22: 75461.
  • 155
    Bogomolski-Yahalom V, Ashur Y, Klein A, Tur-Kaspa R. Hepatitis C virus genotypes in patients with persistent infection – a preliminary report. Isr J Med Sci 1997; 33: 1822.
  • 156
    Ministry of Health Israel, Department of Epidemiology. Infectious Diseases: Morbidity in Israel. Israel Morbidity Report. Ministry of Health Israel, Department of Epidemiology, 2010, 129pp.
  • 157
    Cozzolongo R, Osella AR, Elba S, et al. Epidemiology of HCV infection in the general population: a survey in a southern Italian town. Am J Gastroenterol 2009; 104: 27406.
  • 158
    Fusco M, Girardi E, Piselli P, et al. Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur J Cancer 2008; 44: 84753.
  • 159
    Di Stefano R, Stroffolini T, Ferraro D, et al. Endemic hepatitis C virus infection in a Sicilian town: further evidence for iatrogenic transmission. J Med Virol 2002; 67: 33944.
  • 160
    La Torre G, De Vito E, Langiano E, et al. Epidemiology of hepatitis C virus antibodies in blood donors from the province of Latina, Italy. Eur J Epidemiol 2003; 18: 6914.
  • 161
    Fabris P, Baldo V, Baldovin T, et al. Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol 2008; 42: 52732.
  • 162
    Beggio M, Giraldo M, Borella-Venturini M, et al. Prevalence of hepatitis virus A, B, and C markers according to the geographic origin of medical students. G Ital Med Lav Ergon 2007; 29: 7457.
  • 163
    Petti S, Divizia M, Donia D, et al. Analysis of the shift of the transmission pattern for hepatitis C in a community in Central Italy. New Microbiol 2006; 29: 2079.
  • 164
    Raja M, Azzoni A, Pucci D. Characteristics of HCV positive patients in an Italian urban psychiatric unit. Clin Pract Epidemol Ment Health 2006; 2: 26.
  • 165
    Ansaldi F, Bruzzone B, Salmaso S, et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005; 76: 32732.
  • 166
    Montella M, Crispo A, Grimaldi M, et al. Prevalence of hepatitis C virus infection in different population groups in southern Italy. Infection 2005; 33: 912.
  • 167
    Pendino GM, Mariano A, Surace P, et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 2005; 41: 11519.
  • 168
    Montella M, Crispo A, Serraino D, Rezza G, Franceschi S. Is the spread of HCV in Southern Italy attributable to iatrogenic transmission through unsterile injections? Eur J Cancer Prev 2003; 12: 856.
  • 169
    Cecere A, Marotta F, Lucariello A, et al. High prevalence of hepatitis C virus infection in a southern Italian rural region. Clinical aspects and evidence of inapparent parenteral exposure. Panminerva Med 2003; 45: 2539.
  • 170
    Catalani C, Biggeri A, Gottard A, et al. Prevalence of HCV infection among health care workers in a hospital in central Italy. Eur J Epidemiol 2004; 19: 737.
  • 171
    Proietti L, Origlio A, Sandona PB, Duscio D, Malaguarnera M. Prevalence of HCV in health care workers in Southern Italy. Clin Ter 2003; 154: 15962.
  • 172
    Mazzeo C, Azzaroli F, Giovanelli S, et al. Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance. Gut 2003; 52: 10304.
  • 173
    Bongiorno MR, Pistone G, Arico G. Hepatitis B and hepatitis C virus infections in dermatological patients in west Sicily: a seroepidemiological study. J Eur Acad Dermatol Venereol 2002; 16: 436.
  • 174
    Kondili LA, Chionne P, Costantino A, et al. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut 2002; 50: 6936.
  • 175
    Campello C, Poli A, Dal Molin G, Besozzi-Valentini F. Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in northern Italy. Infection 2002; 30: 712.
  • 176
    Raffaele A, Valenti M, Iovenitti M, et al. High prevalence of HCV infection among the general population in a rural area of central Italy. Eur J Epidemiol 2001; 17: 416.
  • 177
    Baldo V, Floreani A, Menegon T, Angiolelli G, Trivello R. Prevalence of antibodies against hepatitis C virus in the elderly: a seroepidemiological study in a nursing home and in an open population. The Collaborative Group. Gerontology 2001; 46: 1948.
  • 178
    Baldo V, Floreani A, Menegon T, et al. Hepatitis C virus, hepatitis B virus and human immunodeficiency virus infection in pregnant women in North-East Italy: a seroepidemiological study. Eur J Epidemiol 2000; 16: 8791.
  • 179
    Coppola RC, Masia G, Pradat P, et al. Impact of hepatitis C virus infection on healthy subjects on an Italian island. J Viral Hepat 2000; 7: 1307.
  • 180
    Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000; 31: 7515.
  • 181
    Maio G, D'Argenio P, Stroffolini T, et al. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. J Hepatol 2000; 33: 11620.
  • 182
    Maggi G, Armitano S, Brambilla L, et al. Hepatitis C infection in an Italian population not selected for risk factors. Liver 1999; 19: 42731.
  • 183
    Osella AR, Sonzogni L, Cavallini A, et al. Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in southern Italy: a population-based study. J Clin Microbiol 1999; 37: 23712.
  • 184
    Natali A, Dieci E, Pilotti E, Chezzi C. Prevalence of hepatitis C virus antibodies in a clinic-based group of Italians from one geographic area. Clin Microbiol Infect 1999; 5: 1259.
  • 185
    Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999; 44: 87480.
  • 186
    Comandini UV, Tossini G, Longo MA, et al. Sporadic hepatitis C virus infection: a case–control study of transmission routes in a selected hospital sample of the general population in Italy. Scand J Infect Dis 1998; 30: 115.
  • 187
    Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997; 26: 100611.
  • 188
    Tanzi M, Bellelli E, Benaglia G, et al. The prevalence of HCV infection in a cohort of pregnant women, the related risk factors and the possibility of vertical transmission. Eur J Epidemiol 1997; 13: 51721.
  • 189
    Osella AR, Misciagna G, Leone A, Di Leo A, Fiore G. Epidemiology of hepatitis C virus infection in an area of Southern Italy. J Hepatol 1997; 27: 305.
  • 190
    Floreani A, Paternoster D, Zappala F, et al. Hepatitis C virus infection in pregnancy. Br J Obstet Gynaecol 1996; 103: 3259.
  • 191
    Puro V, Petrosillo N, Ippolito G, et al. Occupational hepatitis C virus infection in Italian health care workers. Italian Study Group on Occupational Risk of Bloodborne Infections. Am J Public Health 1995; 85: 12725.
  • 192
    Stroffolini T, Menchinelli M, Taliani G, et al. High prevalence of hepatitis C virus infection in a small central Italian town: lack of evidence of parenteral exposure. Ital J Gastroenterol 1995; 27: 2358.
  • 193
    D'Amelio R, Stroffolini T, Matricardi PM, et al. Low prevalence of anti-HCV antibodies among Italian Air Force recruits. Scand J Infect Dis 1995; 27: 124.
  • 194
    Romano L, Azara A, Chiaramonte M, et al. Low prevalence of anti-HCV antibody among Italian children. Infection 1994; 22: 3502.
  • 195
    Marranconi F, Fabris P, Stecca C, et al. Prevalence of anti-HCV and risk factors for hepatitis C virus infection in healthy pregnant women. Infection 1994; 22: 3337.
  • 196
    Puro V, Lo PE, D'Ascanio I, et al. The seroprevalence of HIV, HBV and HCV infections in patients coming to the departments of general surgery of a public hospital (S. Camillo, Rome). Minerva Chir 1993; 48: 34954.
  • 197
    Gessoni G, Manoni F. Prevalence of anti-hepatitis C virus antibodies among teenagers in the Venetian area: a seroepidemiological study. Eur J Med 1993; 2: 7982.
  • 198
    Campello C, Majori S, Poli A, et al. Prevalence of HCV antibodies in health-care workers from northern Italy. Infection 1992; 20: 2246.
  • 199
    Rapicetta M, Attili AF, Mele A, et al. Prevalence of hepatitis C virus antibodies and hepatitis C virus-RNA in an urban population. J Med Virol 1992; 37: 8792.
  • 200
    Albano A, Pianetti A, Biffi MR, et al. Prevalence of anti-HCV in subjects of various age groups. Eur J Epidemiol 1992; 8: 30911.
  • 201
    Mariano A, Scalia TG, Tosti ME, Spada E, Mele A. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis 2009; 41: 68999.
  • 202
    Tosti ME, Solinas S, Prati D, et al. An estimate of the current risk of transmitting blood-borne infections through blood transfusion in Italy. Br J Haematol 2002; 117: 2159.
  • 203
    Sereno S, Perinelli P, Laghi V. Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users-relation to period of injection started. J Clin Virol 2009; 45: 3547.
  • 204
    Pizzillo P, Almasio PL, Ferraro D, Craxi A, Di Stefano R. HCV genotypes in Sicily: is there any evidence of a shift? J Med Virol 2009; 81: 10406.
  • 205
    Cenci M, Massi M, Alderisio M, De Soccio G, Recchia O. Prevalence of hepatitis C virus (HCV) genotypes and increase of type 4 in central Italy: an update and report of a new method of HCV genotyping. Anticancer Res 2007; 27: 121922.
  • 206
    Cenci M, De Soccio G, Recchia O. Prevalence of hepatitis C virus (HCV) genotypes in central Italy. Anticancer Res 2003; 23: 512932.
  • 207
    Dal Molin G, Ansaldi F, Biagi C, et al. Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. J Med Virol 2002; 68: 3526.
  • 208
    Matera G, Lamberti A, Quirino A, et al. Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy. Diagn Microbiol Infect Dis 2002; 42: 16973.
  • 209
    Dalgard O, Jeansson S, Skaug K, Raknerud N, Bell H. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol 2003; 38: 86470.
  • 210
    Melum E, Schrumpf E, Bjoro K. Liver TX for hepatitis C cirrhosis in a low prevalence population: risk factors and status at evaluation. Scand J Gastroenterol 2006; 41: 5926.
  • 211
    Vik IS, Skaug K, Dalgard O, Steen TW, Hoddevik G. Hepatitis C – a health problem also in Norway. Tidsskr Nor Laegeforen 2008; 128: 5636.
  • 212
    Kristiansen MG, Gutteberg T, Berg LK, et al. Hepatitis C in Northern Norway – an 8-year material. Tidsskr Nor Laegeforen 2002; 122: 19746.
  • 213
    Eskild A, Samdal HH, Skaug K, et al. Hepatitis C virus among pregnant women in Norway – occurrence of antibodies and pregnancy outcome. Tidsskr Nor Laegeforen 2000; 120: 10068.
  • 214
    Nordoy I, Schrumpf E, Elgjo K, et al. Liver disease in anti-hepatitis C virus-positive Norwegian blood donors. Scand J Gastroenterol 1994; 29: 7781.
  • 215
    Dalgard O, Mangia A. Management of patients with hepatitis C virus genotype 2 or 3: comments on updated American Association for the Study of Liver Diseases practice guidelines. Hepatology 2009; 50: 3235.
  • 216
    Dalgard O, Egeland A, Ervik R, et al. Risk factors for hepatitis C among injecting drug users in Oslo. Tidsskr Nor Laegeforen 2009; 129: 1014.
  • 217
    Kielland KB, Siebke JC. Hepatitis A-, B- and C-markers among Norwegian drug addicts in the period 1975–89. Tidsskr Nor Laegeforen 1991; 111: 8214.
  • 218
    Dalgard O. Medical Department, Oslo University Hospital, Rikshospitalet, Oslo, Norway. Estimated incidence of hepatitis C in Norway. Conversation with Wallace C. Center for Disease Analysis, Kromite, Louisville, CO, USA, 18 February 2011.
  • 219
    Bell H, Hellum K, Harthug S, et al. Prevalence of hepatitis C genotypes among patients with chronic hepatitis C in Norway. Construct Group. Scand J Infect Dis 1996; 28: 3579.
  • 220
    Warunek W, Librant-Suska M, Krukowiecki J, et al. Epidemiologic and clinical characteristics of patients with hepatitis type C on the bases of selected parameters. Folia Med Cracov 1996; 37: 719.
  • 221
    Chlabicz S, Flisiak R, Grzeszczuk A, et al. Known and probable risk factors for hepatitis C infection: a case series in north-eastern Poland. World J Gastroenterol 2006; 12: 1415.
  • 222
    Chlabicz S, Grzeszczuk A, Prokopowicz D. Medical procedures and the risk of iatrogenic hepatitis C infection: case–controlled study in north-eastern Poland. J Hosp Infect 2004; 58: 2049.
  • 223
    Labedzka H, Simon K, Gladysz A. Clinical and epidemiological assessment of hepatitis C virus infection among voluntary blood donors. Med Sci Monit 2002; 8: CR5916.
  • 224
    Flisiak R, Halota W, Horban A, et al. Prevalence of anti-HCV and HCV-RNA among health care workers and patients of multispecialistic hospitals in Poland. J Hepatol. 2011; 54(Suppl. 1): S456.
  • 225
    Bielawski K, Wlasiuk M, Truskolawska M, Falkiewicz B. HCV infection in Poland. Arch Med Res 2000; 31: 5325.
  • 226
    Borzecka B, Bludzin W. The program of early detection of HCV infection. Przegl Epidemiol 2007; 61: 7338.
  • 227
    Braczkowska B, Kowalskan M, Zejda JE, et al. Prevalence and basic determinants of hepatitis C antibodies in medical students in Katowice, Poland. Przegl Lek 2006; 63: 53942.
  • 228
    Swincow G, Nowak A, Czarnecki R, Czerwionka-Szaflarska M. Prevalence of HCV infection in infants – own clinical experience. Med Wieku Rozwoj 2006; 10: 40715.
  • 229
    Seyfried H, Brojer E, Grabarczyk P, et al. Prevalence of hepatitis C virus markers in Polish blood donors in 1994–2003. Przegl Epidemiol 2005; 59: 80714.
  • 230
    Chlabicz S, Bonifatiuk I, Radziwon P. Prevalence of hepatitis C virus antibodies among blood donors in north-eastern Poland. Hepatol Res 2005; 33: 20610.
  • 231
    Stepien M, Rosinska M. Hepatitis C in Poland in 2008. Przegl Epidemiol 2010; 64: 24550.
  • 232
    Rosinska M, Czarkowski MP. Hepatitis C in Poland in 2005. Przegl Epidemiol 2007; 61: 2816.
  • 233
    Czarkowski MP. Hepatitis C in Poland in 2004. Przegl Epidemiol 2006; 60: 4816.
  • 234
    Czarkowski MP, Kuszewski K. Hepatitis C in Poland in 2003. Przegl Epidemiol 2005; 59: 3038.
  • 235
    Kuszewski K, Czarkowski MP. Hepatitis C in Poland in 2002. Przegl Epidemiol 2004; 58: 1317.
  • 236
    Bielak A. Hepatitis C in Poland in 2001. Przegl Epidemiol 2003; 57: 1258.
  • 237
    Bobel D, Rosinska M. Hepatitis C in Poland in 2006. Przegl Epidemiol 2008; 62: 32532.
  • 238
    Mazurek J. Hepatitis C in Poland in 2000. Przegl Epidemiol 2002; 56: 3258.
  • 239
    Laskus I, Rosinska M. Hepatitis C in Poland in 2007. Przegl Epidemiol 2009; 63: 2514.
  • 240
    Chlabicz S, Flisiak R, Kowalczuk O, et al. Changing HCV genotypes distribution in Poland – relation to source and time of infection. J Clin Virol 2008; 42: 1569.
  • 241
    Brojer E, Gronowska A, Medynska J, et al. The hepatitis C virus genotype and subtype frequency in hepatitis C virus RNA-positive, hepatitis C virus antibody-negative blood donors identified in the nucleic acid test screening program in Poland. Transfusion 2004; 44: 170610.
  • 242
    Areias J, Gomes H, Mocho ML, et al. Epidemiological characterization of chronic hepatitis C in Portugal. Gastroenterología y hepatología 2006; 29: 1478.
  • 243
    Santos A, Carvalho A, Bento D, et al. Epidemiology of hepatitis C in central Portugal. Prevalence of anti-HCV in the population of the Coimbra District. Acta Med Port 1994; 7: S38.
  • 244
    Marinho RT, Moura MC, Giria JA, Ferrinho P. Epidemiological aspects of hepatitis C in Portugal. J Gastroenterol Hepatol 2001; 16: 10767.
  • 245
    Ramalho F, Costa A, Pires A, et al. Correlation of genotypes and route of transmission with histologic activity and disease stage in chronic hepatitis C. Dig Dis Sci 2000; 45: 1827.
  • 246
    De Carvalho A, Martinho A, Leitao J, et al. HCV genotypes. Liver histopathology and immunologic profile in four groups of patients. Acta Med Port 2000; 13: 6775.
  • 247
    Goldis A. Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Comments on the Romania portion of HCV manuscript. Conversation with Largen A. Center for Disease Analysis, Kromite, Louisville, CO, USA, 15 November 2010.
  • 248
    Grigorescu M. HCV genotype 1 is almost exclusively present in Romanian patients with chronic hepatitis C. J Gastrointestin Liver Dis 2009; 18: 4550.
  • 249
    Gheorghe L, Grigorescu M, Iacob S, et al. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice. Rom J Gastroenterol 2005; 14: 10915.
  • 250
    Gheorghe L, Iacob S, Sporea I, et al. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. J Gastrointestin Liver Dis 2007; 16: 239.
  • 251
    Gheorghe L, Iacob S, Csiki IE. Prevalence of hepatitis C in Romania: different from European rates? J Hepatol 2008; 49: 6612.
  • 252
    Azoicai D, Ivan A, Carasievici E, et al. The prevalence of the owner of serologic markers for the hepatitis C virus, in a north-eastern territory of Romania. Rev Med Chir Soc Med Nat Iasi 2001; 105: 12731.
  • 253
    Ivan A, Azoicai D, Filimon R, et al. The epidemiological aspects and prevalence of markers in those with viral hepatitis C in some population categories in 1994–1997 in Iasi County. Bacteriol Virusol Parazitol Epidemiol 1998; 43: 2759.
  • 254
    Ivan A, Azoicai D, Grigorescu R, et al. Seroepidemiological considerations of the incidence of viral hepatitis C in some population groups. Rev Med Chir Soc Med Nat Iasi 1995; 99: 12938.
  • 255
    Molnar GB, Popa S, Jebeleanu L, Damian C. A prevalence study of serum markers in hepatitis virus infection in the epidemiological anamnesis of the population. Bacteriol Virusol Parazitol Epidemiol 1994; 39: 14150.
  • 256
    Paquet C, Babes VT, Drucker J, Senemaud B, Dobrescu A. Viral hepatitis in Bucharest. Bull World Health Organ 1993; 71: 7816.
  • 257
    Russian Federation MoH. Viral hepatitis prophylaxis, general rules of epidemiology surveillance for viral hepatitis. Russian Federation Ministry of Health, 2000.
  • 258
    Mikhailov MI, Gomberg MA, Dolzhanskaya NA, Koubanova AA. Significance of sexual route of transmission of hepatitis B and C in Russia. Int J STD AIDS 2002; 13 (Suppl. 2): 911.
  • 259
    Abdourakhmanov DT, Hasaev AS, Castro FJ, Guardia J. Epidemiological and clinical aspects of hepatitis C virus infection in the Russian Republic of Daghestan. Eur J Epidemiol 1998; 14: 54953.
  • 260
    Gaidarenko AD. Prediction of Epidemic of Hepatitis C through Computer Simulation. Moscow: Scientific Research Institute of epidemiology and microbiology. N.F. Gamalei Russian Academy of medical sciences, 2009.
  • 261
    Zhiburt EB, Asadi AK, Cherkasov EG, Reizman PV. The verification of the results of screening antibodies to hepatitis C virus in blood donors. Zh Mikrobiol Epidemiol Immunobiol 2005; 5: 713.
  • 262
    Reshetnikov OV, Khryanin AA, Teinina TR, Krivenchuk NA, Zimina IY. Hepatitis B and C seroprevalence in Novosibirsk, western Siberia. Sex Transm Infect 2001; 77: 463.
  • 263
    Kuzin SN, Lisitsina EV, Samokhvalov EI, et al. Spread of hepatitis C and separate genotypes of hepatitis C virus in a region with a moderately active epidemic process. Vopr Virusol 1999; 44: 7982.
  • 264
    Ariamkina OL, Grigor'ev I, Fadeeva GE, et al. The diagnosis of hepatitis C viral infection in blood donors and patients. Zh Mikrobiol Epidemiol Immunobiol 1998; 1: 747.
  • 265
    Lytsar BN, Skvortsov SV, Poliakova II, Lobanova VI, Belov EV. Detection of antibodies to hepatitis C virus in blood donors. Gematol Transfuziol 1993; 38: 2931.
  • 266
    Sychev A, Mikhailov MI. The hepatitis C virus infection of Moscow blood donors. Zh Mikrobiol Epidemiol Immunobiol 1993; 4: 803.
  • 267
    Zhiburt EB, Danil'chenko VV, Bel'gesov NV, et al. Specific and substitute markers of hepatitis C in screening donor blood. Gematol Transfuziol 1995; 40: 168.
  • 268
    Abe K, Hayakawa E, Sminov AV, et al. Molecular epidemiology of hepatitis B, C, D and E viruses among children in Moscow, Russia. J Clin Virol 2004; 30: 5761.
  • 269
    Ohba K, Mizokami M, Kato T, et al. Seroprevalence of hepatitis B virus, hepatitis C virus and GB virus-C infections in Siberia. Epidemiol Infect 1999; 122: 13943.
  • 270
    Iashina TL, Favorov MO, Shakhgil'dian IV, et al. The spread of hepatitis C markers among the population of regions of Russia and Central Asia. Zh Mikrobiol Epidemiol Immunobiol 1993; 5: 469.
  • 271
    Lvov DK, Samokhvalov EI, Tsuda F, et al. Prevalence of hepatitis C virus and distribution of its genotypes in Northern Eurasia. Arch Virol 1996; 141: 161322.
  • 272
    Onishchenko GG, Shakhgil'dian IV. The current problems in the epidemiology and prevention of viral hepatitis B and C in the Russian Federation. Zh Mikrobiol Epidemiol Immunobiol 2000; 1: 504.
  • 273
    Sagalova O. Chelyabinsk State Medical Academy, Chelyabinsk, Russian Federation. Hepatitis C in Russia from the Ministry of Health and Social Development. Conversation with Razavi HA. Center for Disease Analysis, Kromite, Louisville, CO, USA, 15 July 2010.
  • 274
    Asratian AA, Isaeva OV, Mikhailov MI. Tendency and analysis of the epidemic situation in parenteral virus hepatitis B and C in the Russian Federation and a number of its regions. Zh Mikrobiol Epidemiol Immunobiol 2005; 4: 405.
  • 275
    Shustov AV, Kochneva GV, Sivolobova GF, et al. Molecular epidemiology of the hepatitis C virus in Western Siberia. J Med Virol 2005; 77: 3829.
  • 276
    Maksyutov RA, Gavrilova EV, Kanev AN. The distribution of genotypes of hepatitis C in the Russian regions. Annual All-Russian Congress on Infectious Diseases, Moscow, 29–31 March 2010, Moscow, 186.
  • 277
    Ariamkina OL. HCV infection in Ulyanovsk region. Epidemiologiia i infektsionnye bolezni. Epidemiol Infect Dis 2005; 4: 149.
  • 278
    Kovalev SI, Maliushenko OI, Glinskikh NP. Genetic variations of hepatitis C virus circulating in the Ural region. Vopr Virusol 2003; 48: 114.
  • 279
    L'vov DK, Mishiro S, Selivanov NA, et al. Prevalence of genotypes of the hepatitis C virus, circulating in northwestern and central parts of Russia. Vopr Virusol 1995; 40: 2513.
  • 280
    Echevarria JM, Leon P, Pozo F, Avellon A. Follow-up of the prevalence of hepatitis C virus genotypes in Spain during a nine-year period (1996–2004). Enferm Infecc Microbiol Clin 2006; 24: 205.
  • 281
    Martinez-Bauer E, Forns X, Armelles M, et al. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol 2008; 48: 207.
  • 282
    Bruguera M, Forns X, Trapero-Marugan M, et al. Hepatitis C in Spain. Sustained virological response to peginterferon plus ribavirin in chronic hepatitis C genotype 1 patients is associated with a persistent Th1 immune response. Med Clin 2006; 127: 1137.
  • 283
    Martinez SM, Delgado MB, Castroagudin JF, Aguilera A. High rate of infection with hepatitis C virus genotype 4 in a district of galicia, Spain. J Clin Microbiol 2005; 43: 54034.
  • 284
    Sola R, Cruz De Castro E, Hombrados M, et al. Prevalence of hepatitis B and hepatitis C viruses in different counties of Catalonia, Spain: cross-sectional study. Med Clin 2002; 119: 905.
  • 285
    Dominguez A, Bruguera M, Vidal J, Plans P, Salleras L. Community-based seroepidemiological survey of HCV infection in Catalonia, Spain. J Med Virol 2001; 65: 68893.
  • 286
    Forns X, Martinez-Bauer E, Feliu A, et al. Nosocomial transmission of HCV in the liver unit of a tertiary care center. Hepatology 2005; 41: 11522.
  • 287
    Riestra S, Fernandez E, Leiva P, et al. Prevalence of hepatitis C virus infection in the general population of northern Spain. Eur J Gastroenterol Hepatol 2001; 13: 47781.
  • 288
    Chimeno MM, Chocarro A, Brezmes P, Ochoa C, Perez J. Seroprevalence of hepatitis C virus in the general population. Enferm Infecc Microbiol Clin 2002; 20: 647.
  • 289
    Suarez Gonzalez A, Solis Sanchez G, Otero Guerra L, et al. Prevalence of immunity to hepatitis viruses in pregnant women from the health area of Gijon (Spain). Gastroenterol Hepatol 2004; 27: 34752.
  • 290
    Gutierrez-Zufiaurre N, Sanchez-Hernandez J, Munoz S, et al. Seroprevalence of antibodies against Treponema pallidum, Toxoplasma gondii, rubella virus, hepatitis B and C virus, and HIV in pregnant women]. Enferm Infecc Microbiol Clin 2004; 22: 5126.
  • 291
    Munoz-Almagro C, Juncosa T, Fortuny C, et al. Prevalence of hepatitis C virus in pregnant women and vertical transmission. Med Clin 2002; 118: 4524.
  • 292
    Prieto Domingo JJ, Carrion Bolanos JA, Bandres MF. Prevalence of hepatitis C virus and excessive consumption of alcohol in a nonhospital worker population. Gastroenterol Hepatol 1997; 20: 47983.
  • 293
    Suarez A, Viejo G, Navascues CA, et al. The prevalence of hepatitis A, B and C viral markers in the population of Gijon between 26 and 65 years old. Gastroenterol Hepatol 1997; 20: 34752.
  • 294
    Ferrer F, Candela MJ, Garcia C, et al. A comparative study of two third-generation anti-hepatitis C virus ELISAs. Haematologica 1997; 82: 6901.
  • 295
    Munoz-Gomez R, Garcia-Monzon C, Garcia-Buey L, et al. Hepatitis C virus infection in Spanish volunteer blood donors: HCV RNA analysis and liver disease. Eur J Gastroenterol Hepatol 1996; 8: 2737.
  • 296
    Garcia-Bengoechea M, Emparanza JI, Sarriugarte A, et al. Antibodies to hepatitis C virus: a cross-sectional study in patients attending a trauma unit or admitted to hospital for elective surgery. Eur J Gastroenterol Hepatol 1995; 7: 23741.
  • 297
    Suarez A, Rodriguez M, Riestra S, et al. The prevalence of anti-HCV positivity among blood donors in Asturias. A clinical–epidemiologic study. Med Clin 1994; 103: 60610.
  • 298
    Esteban JI, Lopez-Talavera JC, Genesca J, et al. Evaluation of anti-HCV positive blood donors identified during routine screening. Arch Virol Suppl 1992; 4: 2446.
  • 299
    Esteban JI, Lopez-Talavera JC, Genesca J, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991; 115: 4439.
  • 300
    Martinez JL, del Hierro J, Camarero A, et al. Hepatitis C virus infection in different risk groups and among blood donors. Enferm Infecc Microbiol Clin 1991; 9: 34550.
  • 301
    Martin Y, Marzo L, Cinto F, Delgado P, Bunuel C. Incidence of anti-HCV and ALT in blood donors. Sangre 1990; 35: 197200.
  • 302
    Salmeron J, Gimenez F, Torres C, et al. Epidemiology and prevalence of seropositivity for hepatitis C virus in pregnant women in Granada. Rev Esp Enferm Dig 1998; 90: 84150.
  • 303
    Sacristan B, Gastanares MI, Elena A, et al. Seroepidemiologic study of hepatitis C virus infection in a general population from the region of La Rioja, Spain. Med Clin 1996; 107: 3315.
  • 304
    Gil Miguel A, Ruedas A, Santos Santos M, Rey Calero YJ. Prevalence of hepatitis C virus infection in school children in an urban and suburban area of Madrid. Aten Primaria 1996; 17: 5212.
  • 305
    Garcia-Fulgueiras A, Tormo MJ, Rodriguez T, et al. Prevalence of hepatitis B and C markers in the south-east of Spain: an unlinked community-based serosurvey of 2,203 adults. Scand J Infect Dis 1996; 28: 1720.
  • 306
    Salleras L, Bruguera M, Vidal J, et al. Seroepidemiology of hepatitis C virus infection in pregnant women in Catalonia. Med Clin 1994; 103: 7214.
  • 307
    Jaqueti J, Navarro-Gallar F, Martinez-Hernandez D, et al. Prevalence of antibodies against the hepatitis C virus among the staff of a general hospital. Rev Esp Enferm Dig 1991; 80: 334.
  • 308
    Muga R, Sanvisens A, Bolao F, et al. Significant reductions of HIV prevalence but not of hepatitis C virus infections in injection drug users from metropolitan Barcelona: 1987–2001. Drug Alcohol Depend 2006; 82 (Suppl. 1): S2933.
  • 309
    Lumbreras B, Jarrin I, del Amo J, et al. Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. AIDS 2006; 20: 1116.
  • 310
    Jimenez Fabrega X, Carballo AA, Batalla MC, et al. The prevalence of infection by the hepatitis B, C and human immunodeficiency viruses in drug users. Aten Primaria 1999; 24: 36871.
  • 311
    Santana Rodriguez OE, Male Gil ML, HernandezSantana JF, Liminana Canal JM, Martin Sanchez AM. Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain. Eur J Epidemiol 1998; 14: 55561.
  • 312
    Bolumar F, Hernandez-Aguado I, Ferrer L, et al. Prevalence of antibiotics to hepatitis C in a population of intravenous drug users in Valencia, Spain, 1990–1992. Int J Epidemiol 1996; 25: 2049.
  • 313
    Payeras Cifre A, Socias Moya M, Forteza-Rei Borralleras J, Besalduch Vidal J. Hepatitis C viral infection and the consumption of intravenous drugs. Rev Sanid Hig Publica 1992; 66: 2337.
  • 314
    Ramos B, Nunez M, Toro C, et al. Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients. J Infect 2007; 54: 1739.
  • 315
    Fernandez-Arcas N, Lopez-Siles J, Trapero S, et al. High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): phylogenetic and epidemiological analyses. J Med Virol 2006; 78: 142935.
  • 316
    Moreno Planas JM, Fernandez Ruiz M, Portero Azorin F, et al. Prevalence of hepatitis C virus genotypes in a Spanish liver transplant unit. Transplant Proc 2005; 37: 14867.
  • 317
    Rodriguez JC, Garcia J, Moya I, et al. Genetic variability of hepatitis C virus in the health area of Elche (Spain). Correlation between core antigen and viral load. Gastroenterol Hepatol 2003; 26: 40710.
  • 318
    Duberg A, Janzon R, Back E, Ekdahl K, Blaxhult A. The epidemiology of hepatitis C virus infection in Sweden. Euro Surveill 2008; 13: 15.
  • 319
    Duberg AS, Pettersson H, Aleman S, et al. The burden of hepatitis C in Sweden: a national study of inpatient care. J Viral Hepat 2011; 18: 10618.
  • 320
    Shev S, Widell A, Foberg U, et al. HCV genotypes in Swedish blood donors as correlated to epidemiology, liver disease and hepatitis C virus antibody profile. Infection 1995; 23: 2537.
  • 321
    Lidman C, Norden L, Kaberg M, et al. Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. Scand J Infect Dis 2009; 41: 67984.
  • 322
    Hoffmann G, Berglund G, Elmstahl S, et al. Prevalence and clinical spectrum of chronic viral hepatitis in a middle-aged Swedish general urban population. Scand J Gastroenterol 2000; 35: 8615.
  • 323
    Struve J, Norrbohm O, Stenbeck J, Giesecke J, Weiland O. Risk factors for hepatitis A, B and C virus infection among Swedish expatriates. J Infect 1995; 31: 2059.
  • 324
    Lindholm A. Epidemiology of viral infections in the Swedish blood-donor population. Blood Coagul Fibrinolysis 1994; 5: S137.
  • 325
    European Centre for Disease Prevention and Control. Annual Epidemiological Report on Communicable Diseases in Europe 2008. Report on the State of Communicable Diseases in the EU and EEA/EFTA Countries. European Centre for Disease Prevention and Control, 2008.
  • 326
    Lindh M, Hannoun C. Genotyping of hepatitis C virus by Taqman real-time PCR. J Clin Virol 2005; 34: 10814.
  • 327
    Widell A, Verbaan H, Wejstal R, et al. Hepatocellular carcinoma in Sweden: its association with viral hepatitis, especially with hepatitis C viral genotypes. Scand J Infect Dis 2000; 32: 14752.
  • 328
    Westin J, Lindh M, Lagging LM, Norkrans G, Wejstal R. Chronic hepatitis C in Sweden: genotype distribution over time in different epidemiological settings. Scand J Infect Dis 1999; 31: 3558.
  • 329
    Widell A, Shev S, Mansson S, et al. Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using type specific primers: epidemiological applications. J Med Virol 1994; 44: 2729.
  • 330
    Prasad L, Spicher VM, Zwahlen M, et al. Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol 2007; 36: 7317.
  • 331
    Prasad L, Spicher VM, Negro F, Rickenbach M, Zwahlen M. Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study. J Viral Hepat 2009; 16: 6449.
  • 332
    Federal Office of Public Health (FOPH). Health in Switzerland, Switzerland, 27 August 2010.
  • 333
    Gerlich M, Gschwend P, Uchtenhagen A, Kramer A, Rehm J. Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002. Eur J Epidemiol 2006; 21: 5459.
  • 334
    Steffen T, Blattler R, Gutzwiller F, Zwahlen M. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. Eur J Public Health 2001; 11: 42530.
  • 335
    Ladewig D. A reduction in HIV positive and an increase in hepatitis C positive subjects in methadone maintenance treatments. Swiss Med Wkly 2001; 131: 422.
  • 336
    Broers B, Junet C, Bourquin M, et al. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS 1998; 12: 205966.
  • 337
    Diamantis I, Bassetti S, Erb P, et al. High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. J Hepatol 1997; 26: 7947.
  • 338
    Russmann S, Dowlatshahi EA, Printzen G, et al. Prevalence and associated factors of viral hepatitis and transferrin elevations in 5036 patients admitted to the emergency room of a Swiss university hospital: cross-sectional study. BMC Gastroenterol 2007; 7: 5.
  • 339
    Ambuhl PM, Binswanger U, Renner EL. Epidemiology of chronic hepatitis B and C among dialysis patients in Switzerland. Schweiz Med Wochenschr 2000; 130: 3418.
  • 340
    Candinas D, Joller-Jemelka HI, Schlumpf R, et al. Hepatitis C RNA prevalence in a Western European organ donor pool and virus transmission by organ transplantation. J Med Microbiol 1994; 41: 2203.
  • 341
    Zucca E, Roggero E, Maggi-Solca N, et al. Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin's lymphoma patients in Southern Switzerland. Haematologica 2000; 85: 14753.
  • 342
    Weber C, Collet S, Fried R, et al. Low prevalence of hepatitis C virus antibody among Swiss dental health care workers. J Hepatol 2001; 34: 9634.
  • 343
    Lavanchy D, Mayerat C, Morel B, et al. Evaluation of third-generation assays for detection of anti-hepatitis C virus (HCV) antibodies and comparison with presence of HCV RNA in blood donors reactive to c100-3 antigen. J Clin Microbiol 1994; 32: 22725.
  • 344
    Prasad LR, Massery Spicher V, Kammerlander R, Zwahlen M. Hepatitis C in a sample of pregnant women in Switzerland: seroprevalence and socio-demographic factors. Swiss Med Wkly 2007; 137: 2732.
  • 345
    Sagmeister M, Renner EL, Mullhaupt B, Wong JB. Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol Hepatol 2002; 14: 2534.
  • 346
    Negro F. Divisions of Clinical Pathology and of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland. Newly diagnosed case data from the Swiss Federal Office of Public Health. Conversation with Razavi HA. Center for Disease Analysis, Kromite, Louisville, CO, USA, 5 November 2010.
  • 347
    Swiss Federal Statistical Office. The population of Switzerland 2009, Federal Office of Statistics, Bern, 2010, Statistics of Switzerland. 01, Population, 16pp, 30 cm.
  • 348
    Akcam FZ, Uskun E, Avsar K, Songur Y. Hepatitis B virus and hepatitis C virus seroprevalence in rural areas of the southwestern region of Turkey. Int J Infect Dis 2009; 13: 27484.
  • 349
    Turhan V, Ardic N, Eyigun CP, et al. Investigation of the genotype distribution of hepatitis C virus among Turkish population in Turkey and various European countries. Chin Med J 2005; 118: 13924.
  • 350
    Keskin F, Ciftci S, Turkoglu S, Badur S. Transmission routes for chronic hepatitis C and its relation with HCV genotypes. Turk J Gastroenterol 2010; 21: 396400.
  • 351
    Erden S, Buyukozturk S, Calangu S, et al. A study of serological markers of hepatitis B and C viruses in Istanbul, Turkey. Med Princ Pract 2003; 12: 1848.
  • 352
    Tozun N, Ozdogan OC, Cakaloglu Y. A nationwide prevalence study and risk factors for hepatitis A, B, C,and D infections in Turkey (abstract). Hepatology 2010; 52 (Suppl.): 697A.
  • 353
    Dursun M, Ozekinci T, Ertem M, et al. Prevalence of Hepatitis C in adults in the south-eastern region of Anatolia: a community-based study. Hepatol Res 2004; 29: 7580.
  • 354
    Yildirim B, Barut S, Bulut Y, et al. Seroprevalence of hepatitis B and C viruses in the province of Tokat in the Black Sea region of Turkey: a population-based study. Turk J Gastroenterol 2009; 20: 2730.
  • 355
    Gunduz T, Mumcuoglu I, Guray M. Evaluation of hepatitis B surface antigen, anti-hepatitis C virus and anti-human immunodeficiency virus antibodies and syphilis seropositivity in blood donors: six years' seropositivity. Int J Clin Pharmacol Res 2005; 25: 1558.
  • 356
    Afsar I, Gungor S, Sener AG, Yurtsever SG. The prevalence of HBV, HCV and HIV infections among blood donors in Izmir, Turkey. Indian J Med Microbiol 2008; 26: 2889.
  • 357
    Gurol E, Saban C, Oral O, Cigdem A, Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol 2006; 21: 299305.
  • 358
    Kocak N, Hepgul S, Ozbayburtlu S, et al. Trends in major transfusion-transmissible infections among blood donors over 17 years in Istanbul, Turkey. J Int Med Res 2004; 32: 6715.
  • 359
    Mutlu B, Meric M, Willke A. Seroprevalence of hepatitis B and C virus, human immunodeficiency virus and syphilis in the blood donors. Mikrobiyol Bul 2004; 38: 4458.
  • 360
    Altindis M, Yilmaz S, Dikengil T, Acemoglu H, Hosoglu S. Seroprevalence and genotyping of hepatitis B, hepatitis C and HIV among healthy population and Turkish soldiers in Northern Cyprus. World J Gastroenterol 2006; 12: 67926.
  • 361
    Sakarya S, Oncu S, Ozturk B, Oncu S. Effect of preventive applications on prevalence of hepatitis B virus and hepatitis C virus infections in West Turkey. Saudi Med J 2004; 25: 10702.
  • 362
    Demirturk N, Demirdal T, Toprak D, Altindis M, Aktepe OC. Hepatitis B and C virus in West-Central Turkey: seroprevalence in healthy individuals admitted to a university hospital for routine health checks. Turk J Gastroenterol 2006; 17: 26772.
  • 363
    Thomas DL, Mahley RW, Badur S, Palaoglu E, Quinn TC. The epidemiology of hepatitis C in Turkey. Infection 1994; 22: 4114.
  • 364
    Ozgun MT, Batukan C, Mazicioglu MM, et al. Intrauterine device use does not increase the incidence of anti-hepatitis C seropositivity among monogamous women in Turkey. Contraception 2009; 80: 2615.
  • 365
    Altinbas S, Erdogan M, Danisman N. The seroprevalences of HBs Ag and anti-HCV in pregnant women in Ankara. Arch Gynecol Obstet 2010; 281: 371.
  • 366
    Alim A, Artan MO, Baykan Z, Alim BA. Seroprevalence of hepatitis B and C viruses, HIV, and syphilis infections among engaged couples. Saudi Med J 2009; 30: 5415.
  • 367
    Maral I, Dogruman-Al F, Bakar C, et al. Hepatitis B virus and hepatitis C virus seroprevalence in the elderly living in nursing homes. J Investig Med 2009; 57: 7179.
  • 368
    Altuglu I, Soyler I, Ozacar T, Erensoy S. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. Int J Infect Dis 2008; 12: 23944.
  • 369
    Bozdayi AM, Aslan N, Bozdayi G, et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol 2004; 149: 211529.
  • 370
    Abacioglu YH, Davidson F, Tuncer S, et al. The distribution of hepatitis C virus genotypes in Turkish patients. J Viral Hepat 1995; 2: 297301.
  • 371
    Costella, Annastella and Health Protection Agency United Kingdom. Hepatitis C in the UK 2008. The Health Protection Agency Annual Report. Health Protection Agency Centre for Infections, London, 2008.
  • 372
    Health Protection Scotland. Blood Borne Viruses and Sexually Transmitted Infections. Hepatitis C Reporting. Table 3: Persons in Scotland reported to be hepatitis C antibody positive, by age group at time of earliest positive specimen and year of earliest positive specimen, 2010, 31 December 2009, Available at http://www.documents.hps.scot.nhs.uk/bbvsti/annual-data-tables/2010/hcv-table3-2010-05.pdf (accessed 17 September 2010).
  • 373
    Hutchinson SJ, Roy KM, Wadd S, et al. Hepatitis C virus infection in Scotland: epidemiological review and public health challenges. Scott Med J 2006; 51: 815.
  • 374
    De Angelis D, Sweeting M, Ades A, et al. An evidence synthesis approach to estimating Hepatitis C prevalence in England and Wales. Stat Methods Med Res 2009; 18: 36179.
  • 375
    Goldberg D, Brown G, Hutchinson S, et al. Hepatitis C Action Plan for Scotland: Phase II (May 2008–March 2011). Euro Surveill 2008; 13: 12.
  • 376
    Sweeting MJ, Hope VD, Hickman M, et al. Hepatitis C infection among injecting drug users in England and Wales (1992–2006): there and back again? Am J Epidemiol 2009; 170: 35260.
  • 377
    Balogun MA, Murphy N, Nunn S, et al. Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics. Epidemiol Infect 2009; 137: 9807.
  • 378
    Hickman M, Hope V, Coleman B, et al. Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J Public Health 2009; 31: 37482.
  • 379
    Hickman M, Hope V, Brady T, et al. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepat 2007; 14: 64552.
  • 380
    Roy KM, Hutchinson SJ, Wadd S, et al. Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them. Epidemiol Infect 2007; 135: 43342.
  • 381
    Judd A, Hickman M, Jones S, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005; 330: 245.
  • 382
    Balogun MA, Ramsay ME, Parry JV, et al. A national survey of genitourinary medicine clinic attenders provides little evidence of sexual transmission of hepatitis C virus infection. Sex Transm Infect 2003; 79: 3016.
  • 383
    Hope VD, Judd A, Hickman M, et al. Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working? Am J Public Health 2001; 91: 3842.
  • 384
    Taylor A, Goldberg D, Hutchinson S, et al. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990–1996: are current harm reduction strategies working? J Infect 2000; 40: 17683.
  • 385
    Edeh J, Spalding P. Screening for HIV, HBV and HCV markers among drug users in treatment in rural south-east England. J Public Health Med 2000; 22: 5319.
  • 386
    Lamden KH, Kennedy N, Beeching NJ, et al. Hepatitis B and hepatitis C virus infections: risk factors among drug users in Northwest England. J Infect 1998; 37: 2609.
  • 387
    Watson JP, Brind AM, Chapman CE, et al. Hepatitis C virus: epidemiology and genotypes in the north east of England. Gut 1996; 38: 26976.
  • 388
    Mutimer DJ, Harrison RF, O'Donnell KB, et al. Hepatitis C virus infection in the asymptomatic British blood donor. J Viral Hepat 1995; 2: 4753.
  • 389
    Garson JA, Clewley JP, Simmonds P, et al. Hepatitis C viraemia in United Kingdom blood donors. A multicentre study. Vox Sang 1992; 62: 21823.
  • 390
    Balogun MA, Vyse AJ, Hesketh LM, et al. Estimating hepatitis C infection acquired in England, 1986–2000. Epidemiol Infect 2009; 137: 124954.
  • 391
    Hutchinson SJ, Goldberg DJ, King M, et al. Hepatitis C virus among childbearing women in Scotland: prevalence, deprivation, and diagnosis. Gut 2004; 53: 5938.
  • 392
    Balogun MA, Ramsay ME, Hesketh LM, et al. The prevalence of hepatitis C in England and Wales. J Infect 2002; 45: 21926.
  • 393
    Goldberg D, McIntyre PG, Smith R, et al. Hepatitis C virus among high and low risk pregnant women in Dundee: unlinked anonymous testing. BJOG 2001; 108: 36570.
  • 394
    Thorburn D, Dundas D, McCruden EA, et al. A study of hepatitis C prevalence in healthcare workers in the West of Scotland. Gut 2001; 48: 11620.
  • 395
    Balogun MA, Ramsay ME, Parry JV, et al. The prevalence and genetic diversity of hepatitis C infection in antenatal clinic attenders in two regions of England. Epidemiol Infect 2000; 125: 70512.
  • 396
    Ades AE, Parker S, Walker J, et al. HCV prevalence in pregnant women in the UK. A study of hepatitis C prevalence in healthcare workers in the West of Scotland. Epidemiol Infect 2000; 125: 399405.
  • 397
    Ward C, Tudor-Williams G, Cotzias T, et al. Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing. Gut 2000; 47: 27780.
  • 398
    Boxall E, Skidmore S, Evans C, Nightingale S. The prevalence of hepatitis B and C in an antenatal population of various ethnic origins. Epidemiol Infect 1994; 113: 5238.
  • 399
    Mohsen AH. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001; 48: 70713.
  • 400
    Harris KA, Gilham C, Mortimer PP, Teo CG. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J Med Virol 1999; 58: 12731.
  • 401
    Saiz dlH, Marco A, Garcia-Guerrero J, Rivera A. Hepatitis C and B prevalence in Spanish prisons. Eur J Clin Microbiol Infect Dis 2011.
  • 402
    Chak E, Talal A, Sherman KE, Schiff E, Saab S. Hepatitis C virus infection in the United States: an estimate of true prevalence. Liver Int 2011. DOI: DOI: 10.1111/j.1478-3231.2011.02494.x.
  • 403
    Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol 2005; 3: 3118.
  • 404
    Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 38398.
  • 405
    Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 90814.
  • 406
    Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899905.
  • 407
    Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 808.
  • 408
    Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21: 98391.
  • 409
    van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009; 136: 160917.
  • 410
    Jauffret-Roustide M, Emmanuelli J, Quaglia M, et al. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data – the ANRS-Coquelicot Study. Subst Use Misuse 2006; 41: 160321.
  • 411
    Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86: 65561.